Because of the unsatisfactory options available for safe and effective antithrombotic therapy, recent, intense research and development efforts have been focused on direct thrombin inhibitors, also known as site-directed thrombin inhibitors. The intravenous agent Novastan (argatroban) is a small-molecule, reversible, direct thrombin inhibitor that is selective for the catalytic site of the thrombin molecule. Argatroban's molecular properties (small molecule; fast, selective, and reversible inhibition of the thrombin catalytic site; and similar in vitro potency for inhibiting both clot-bound and soluble thrombin) offer the potential for significant antithrombotic efficacy with minimal systemic anticoagulant ef fects. Its clinical pharmacologic properties offer the potential for minimal risk of bleeding, very rapid achievement of therapeutic antithrombotic efficacy, predictable dose-response, and rapid restoration of the hemostatic systems to normal upon termination of intravenous infusion. Argatroban is currently approved for clinical use in Japan for the treatment of peripheral arterial occlusive disease. It is in advanced clinical development in North America, South America, and Western Europe for several clinical indications, including (1) adjunctive therapy to thrombolytic agents in the treatment of acute myocardial infarction and (2) antithrombotic therapy for patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome. Key Words: Molecular properties—Novastan (argatroban)—Pharmacology—Thrombin inhibitor.
Get full access to this article
View all access options for this article.
References
1.
Théroux P., Lidon R-M.Anticoagulants and their use in acute ischemic syndromes. In: Topol EJ, ed. A textbook of interventional cardiology. Philadelphia: W. B. Saunders, 1994:23.
2.
Lefkovits J. , Topol EJDirect thrombin inhibitors in cardiovascular medicine. Circulation1994;90:1522.
3.
Hirsh J. Heparin .N Engl J Med1991;324:1565.
4.
Rosenberg RDThe heparin-antithrombin system: a natural anticoagulant mechanism, In: Colman RW, HirschJ, Marder VJ, et al., eds. Hemostasis and thrombosis: principles and clinical practice, 2nd ed. Philadelphia : J. B. Lipincott. 1987:1373.
5.
Hirsh J., Dalen JE, Deykin D., et al. Oral anticoagulation: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest1992;102:312S.
6.
Glazier RLCrowell EBRandomized prospective trial of continuous vs. intermittent heparin therapy . JAMA1976; 236:1365.
7.
Salzman EWDeykin K., Shapiro RM, et al. Management of heparin therapy. N Engl J Med1975;292:1046.
8.
Marcianek E. , Gockerman JPHeparin-induced decrease in circulating antithrombin-IIILancet1977;2:581.
9.
Weitz JI, Huboda M., Massel D., et al. Clot-bound thrombin protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors . J Clin Invest1990;86:385.
10.
Hogg PJ, Jackson CMFibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy. Proc Natl Acad Sci USA1989;86:3619.
11.
Teitel JM, Rosenberg RDProtection of factor Xa from neutralization by the heparin-antithrombin complex . J Clin Invest1983;71:1383.
12.
Loscalzo J. , Melnick B., Handin RIThe interaction of platelet factor 4 and glycosarninoglycans . Arch Biochem Biophys1985;240:446.
13.
Greinacher A.Antigen generation in heparin-associated thrombocytopenia: the nonimmunologic type and the immunologic type are closely linked in their pathogenesis. Semin Thromb Hemost1995;21:106.
14.
Bell WR, Tomasulo PA, Alving BM, et al. Thrombocytopenia occurring during the administration of heparin: a prospective, study in 52 patients. Ann Intern Med1976;85:155.
15.
Visentin GP , Ford SE, Scott JP, et al. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor a completed with heparin or bound to endothelial cells. J Clin Invest1994;93:81.
16.
Kelton JGSheridan D., Brain M., et al. Clinical usefulness of testing for a heparin-dependent platelet aggregating factor in patients with suspected heparin-associated thrombocytopenia . J Lab Clin Med1984;103:606.
17.
Weissman RE, Tobin RWArterial embolism occurring during systemic heparin therapy. Arch Surg1958;76:219.
18.
Wallis DE, Lewis BE, Pifarré R., et al. Active surveillance for heparin-induced thrombocytopenia and thromboembolism. Am Coll Chest Phys1994;Oct. 30.
19.
Magnani HNHeparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with Orgaran (Org 10172). Thromb Haemostas1993;70:554.
Bara L., Billaud E., Gramond G., et al. Comparative pharmacokinetics of low molecular weight (PK 10169) and unfractionated heparin after intravenous and subcutaneous administration . Thromb Res1985;39:631.
22.
Handeland GF , Abidgaard GF, Holm U., et al. Dose-adjusted heparin treatment of deep vein thrombosis: a comparison of unfractionated and low molecular weight heparin. Eur J Clin Pharmacol1990;39:107.
23.
Beguin S., Lindhout T., Hemker HCThe mode of action of heparin in plasma. Thromb Haemostas1989;60:457.
24.
Aster R.Heparin-induced thrombocytopenia and thrombosis. N Engl J Med1995;332:1374.
25.
Callas D., Fareed J.Comparative pharmacology of site directed antithrombin agents. Implication in drug development. Thromb Haemostas1995 ;74:473.
26.
Dodt J., Müller H-P., Seemüller U. et al. The complete amino acid sequence of hirudin, a thrombin specific inhibitor. FEBS Lett1984;165:180.
27.
Bush LRArgatroban, a selective, potent thrombin inhibitor. Card Drug Rev1991;9:247.
28.
Stone SR, Betz A., Parry Maa, et al. Molecular basis for the inhibition of thrombin by hirudin. In: Claeson G, et al., ed. The design of synthetic inhibitors of thrombin. New York: Plenum Press, 1993:35.
29.
Braun PJ, Dennis S., Hofsteenge J., et al. Use of site-directed mutagenesis to investigate the basis for the specificity of hirudin. Biochemistry1988 ;27:6517.
30.
Hijikata A. , Okamoto S.A strategy for a rational approach to designing synthetic selective inhibitors. Semin Thromb Hemost1992; 18:135.
31.
Jackson CMMechanisms of prothrombin activation. In: Colman RW, Hirsh J, Marder VJ, et al., eds. Hemostasis and thrombosis , 2nd ed. Philadelphia: J. B. Lipincott, 1987:1373.
32.
Naski MC, Shafer JAA kinetic model for the a-thrombin-catalyzed conversion of plasma levels of fibrinogen to fibrin in the presence of antithrombin III. J Biol Chem1991;266: 13003.
33.
Lawson JH, Kalafatis M., Stram S., et al. A model for the tissue factor pathway to thrombin. J Biol Chem1994;269: 23357.
34.
Jones KC, et al. A model for the tissue factor pathway to thrombin. J Biol Chem1994;269:23367.
35.
Berry CN, Giradot C., Lecoffre C., et al. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant hirudin . Thromb Haemostas1994;72:381.
36.
Gast A., Tschopp TB, Schmid G., et al. Inhibition of clot-bound and free (fluid-phase thrombin) by a novel synthetic thrombin inhibitor (Ro 46-6240), recombinant hirudin and heparin in human plasma. Blood Coag Fibrin1994;5:879.
37.
Mirshahi M. , Soria J., Soria C., et al. Evaluation of the inhibition by heparin and hirudin of coagulation activation during r-tPA-induced thrombolysis. Blood1989;74:1025.
38.
Rawson TE, VanGorp KA, Yang J., et al. Separation of 21-(R)- and 21-(S)-argatroban: solubility and activity of the individual diastereoisomers. J Pharm Sci1993 ;82:672.
39.
Green D., Ts'ao C., Reynolds N., et al. In vitro studies of a new synthetic thrombin inhibitor. Thromb Res1985;37:145.
40.
Tamao Y., Yamamoto T., Kikumoto R., et al. Effect of a selective thrombin inhibitor MCI-9038 on fibrinolysis in vitro and in vivo. Thromb Haemostas1986 ;56:28.
41.
Berry CH, Girard D., Lochot S., et al. Antithrombotic actions of argatroban in rat models of venous, "mixed" and arterial thrombosis, and its effects on the tail transection bleeding time. Br J Pharmacol1994;113:1209.
42.
Winn MJ, Jain K., Ku DDArgatroban and inhibition of the vasomotor actions of thrombin. J Cardiovasc Pharmacol1993;22:754.
43.
Kumada T., Abiko Y.Comparative study on heparin and a synthetic thrombin inhibitor no. 805 (MD-805) in experimental antithrombin deficient animals. Thromb Res1981;24:285.
44.
Nishiyama H. , Umemura K., Saniabadi AR, et al. Enhancement of thrombolytic efficacy of tissue-type plasminogen activator by adjuvants in the guinea pig thrombosis model. Eur J Pharmacol1994;264.-191.
45.
Mellott MJ, Connelly TM, York SJ, et al. Prevention of reocclusion by MCI-9038, a thrombin inhibitor, following t-PA induced thrombolysis in a canine model of femoreal arterial thrombosis. Thromb Haemostas1990;64:526.
46.
Jang, I-K., Gold HK, Leinbach RC, et al. In vivo thrombin inhibition enhances and sustains arterial recanalization with recombinant tissue plasminogen activator. Circ Res1990;67: 1552.
47.
Fitzgerald DJ, FitzGerald GARole of thrombin and thromboxane A2 in reocclusion following coronary thrombolysis with tissue plasminogen activator . Proc Natl Acad Sci USA1989;86:7585.
48.
Fitzgerald DJ, Wright F., FitzGerald. GAIncreased thromboxane biosynthesis during coronary thrombolysis. Evidence that platelet activation and thromboxane A 2 modulate the response to tissue type plasminogen activator in vivo . Circ Res1989;65:83.
49.
Yasuda T., Gold HK, Yaoita H., et al. Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb/IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue type plasminogen activator in a canine preparation. J Am Coll Cardiol1990;16:714.
50.
Eidt JF, Allison P., Noble S., et al. Thrombin is an important mediator of platelet aggregation in stenosed canine coronary arteries with endothelial injury. J Clin Invest1989;84:18.
51.
lida S.Komatsu T., Hirano T., et al. Pharmacokinetic studies of argipidine (MD-805) in dogs and rabbits. Blood or plasma level profile, metabolism, excretion and accumulation after single or consecutive intravenous administration of argipidine. Oyo Yakuri1986;32:1117.
52.
Callas DD, Hoppensteadt D., Fareed J., et al. Comparative studies on the anticoagulant and protease generation inhibitory actions of newly developed site-directed thrombin inhibitory drugs . Semin Thromb Hemost1995;21:177.
53.
Kaiser B., Fareed J., Hoppensteadt D., et al. Influence of recombinant hirudin and unfractionated heparin on thrombin and factor Xa generation in extrinsic and intrinsic activated systems. Thromb Res1992;65: 157.
54.
Kaiser B., Callas D., Hoppensteadt D., et al. Comparative studies on the inhibitory spectrum of recombinant hirudin, DuP 714 and heparin on the generation of thrombin and factor Xa generation in biochemically defined systems. Thromb Res1994;73:327.
55.
Izawa O., Katsuki M., Komatsu T., et al. Pharmacokinetics studies of argatroban (MD-805) in human concentrations of argatroban and its metabolites in plasma, urine and feces during and after drip intravenous infusion. Jpn Pharm Ther1986;14:251.
56.
Topol EJThrombolytic intervention. In: Topol EJ, ed. A textbook of interventional cardiology. Philadelphia : W. B. Saunders, 1994 :68.
57.
The GUSTO Investigators.An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med1993;329:673.
58.
The GUSTO Angiographic Investigators.The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction . N Engl J Med1993;329:1615.
59.
Becker RCImproving the efficacy and stability of coronary reperfusion following thrombolysis: exploring the thrombin hypothesis. J Thromb Thrombolysis1995;1:133.
60.
Cannon CP, McCabe CH, Henry TD, et al. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the thrombolysis and myocardial infarction (TIMI) 5 trial. J Am Coll Cardiol1994;23:993.
61.
Lee LV, for the TIMI 6 Investigators.Initial experience with hirudin and streptokinase in acute myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) 6 trial. Am J Cardiol1995;75:7.
62.
Antman EM, for the TIMI 9A Investigators.Hirudin in acute myocardial infarction: safety report from the thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9A trial: Circulation1994;90:1624.
63.
GustoIIa Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation1994;90:1631.
64.
Neuhaus K-L. , Essen R., Tebbe U. et al. Safety observations from the pilot phase of the randomized r-hirudin for improvement of thrombolysis (HIT-III) study: a study of the Arbeitsgemeinschaft Lfeitender Kardiologischer Krankenhausärzte (ALKK). Circulation1994;90: 1638.
65.
Sobel BEIntracranial bleeding, fibrinolysis, and anticoagulation: causal connections and clinical implications. Circulation1994 ;90:2147.
66.
Théroux P., Perez-Villa F., Waters D., et al. Randomized double-blind comparison of two doses of hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction. Circulation1994;91:2132.
67.
Gold HK, Torres FW, Garabedian HD, et al. Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris. J Am Coll Cardiol1993;21:1039.
68.
Théroux P., Waters D., Lam J., et al. Reactivation of unstable angina following discontinuation of heparin . N Engl J Med1992;327:141.
69.
Willerson JT , Casscells W.Thrombin inhibitors in unstable angina: rebound or continuation of angina after argatroban withdrawal?J Am Coll Cardiol1993;21:1048.
70.
Zoldhelyi P. , Bichier J., Owen WG, et al. Persistent thrombin generation in humans during specific thrombin inhibition with hirudin. Circulation1994;90:2671.
71.
Becker RC, Bovill EG, Corrao JM, et al. Dynamic nature of thrombin generation, fibrin formation, and platelet activation in unstable angina and non-Q-wave myocardial infarction . J Thromb Thrombolysiv1995;2:57.
72.
Demers C., Ginsberg JS, Brill-Edwards P., et al. Rapid anticoagulation using ancrod for heparin-induced thrombocytopenia . Blood1991;78:2194.
73.
Lewis BE, Leya FS, Wallis D., et al. Failure of ancrod in the treatment of heparin-induced arterial thrombosis. Can J Cardiol1994;10:559.
